Nobel in Chemistry Honors CRISPR/Cas9 Genome Editing

Posted by ISPE Boston
On October 15, 2020

The 2020 Nobel Prize in Chemistry has been awarded to Jennifer Doudna of the University of California, Berkeley and Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens, Berlin, Germany “for the development of a method for genome editing,” specifically the CRISPR/Cas9 genetic scissors. Using this tool, researchers can change the DNA […]

Biogen to Invest $250 Million to Eliminate Its Use of Fossil Fuels

Posted by ISPE Boston
On October 15, 2020

Biogen has undertaken a $250 million, 20-year initiative to eliminate fossil fuels across its operations and collaborate with renowned institutions, including MIT and the Harvard T.H. Chan School of Public Health, with the aim to improve health, especially for the world’s most vulnerable populations. Building on its long-standing commitment to corporate responsibility, Biogen’s goal is […]

Regeneron Submits EUA Request for Antibody Treatment for COVID-19

Posted by ISPE Boston
On October 15, 2020

Regeneron has submitted a request to the FDA for an Emergency Use Authorization (EUA) for their REGN-COV2 investigational antibody combination for COVID-19. Under the company’s agreement with the U.S. government for the initial doses of REGN-COV2, if an EUA is granted the government has committed to making these doses available to the American people at […]

Lilly Reports Progress on mAB Treatment for COVID-19

Posted by ISPE Boston
On October 15, 2020

Data from a new interim analysis of Lilly’s Phase 2 clinical trial showed that combination therapy with two of Lilly’s SARS-CoV-2 neutralizing antibodies reduced viral load, symptoms and COVID-related hospitalization and ER visits. The study evaluated LY-CoV555 and LY-CoV016, both monoclonal antibodies which bind complementary regions of the SARS-CoV-2 spike protein, for the treatment of symptomatic COVID-19 […]

BU Conference Targets Proactive Approaches to Healthcare

Posted by ISPE Boston
On October 15, 2020

On Friday, October 30, 2020 Boston University Questrom School of Business is hosting its 8th Annual Health & Life Sciences Conference. The theme of this year’s conference is “Healthcare 2025: Staying Ahead of the Curve,” and will explore how healthcare stakeholders are responding to challenges, access, and coverage disparities. This is an all-day, virtual conference […]

BMS to Acquire MyoKardia & Heart Drugs for $13 Billion

Posted by ISPE Boston
On October 8, 2020

Bristol Myers Squibb and MyoKardia have entered into a definitive merger agreement under which BMS will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the BMS and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020. MyoKardia is a […]

Walden Biosciences Launches, Targets Kidney Disease

Posted by ISPE Boston
On October 8, 2020

Walden Biosciences, headquartered in Cambridge, has launched with a $51 million Series A financing led by ARCH Venture Partners and UCB Ventures. Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. The majority of renal drug development approaches focus on […]

Moderna Awarded $56 Million for Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics

Posted by ISPE Boston
On October 8, 2020

Moderna has received a commitment of up to $56 million from the Defense Advanced Research Projects Agency (DARPA) to fund the development of a mobile manufacturing protype that is capable of rapidly producing messenger RNA (mRNA) vaccines and therapeutics. The agreement builds on a previous assistance grant with DARPA established in 2013. The award is […]

Dewpoint Therapeutics Raises $77M for Drugs Targeting Biomolecular Condensates

Posted by ISPE Boston
On October 8, 2020

Dewpoint Therapeutics has raised $77 million in a Series B financing round led by ARCH Venture Partners, with participation from both new and existing investors. “We are delighted to have ARCH Venture Partners lead this financing, and to welcome new investors into the condensate field,” said Amir Nashat, managing partner of Polaris Partners and interim […]

About Biomolecular Condensates

Posted by ISPE Boston
On October 8, 2020

Biomolecular condensates, formed through a process called phase separation, are membraneless droplets inside cells that facilitate molecular interactions and help cells perform vital functions. Condensates have been shown to play a critical role in key biological processes and in serious, intractable diseases across areas including neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic […]

Page 58 of 118«‹56 575859 60 ›»